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a b s t r a c t
Cysteine is one of the most reactive amino acids. This is due to the electronegativity of sulphur atom in
the side chain of thiolate group. It results in cysteine being present in several distinct redox forms inside
the cell. Amongst these, reversible oxidations, S-nitrosylation and S-sulfenylation are crucial mediators of
intracellular redox signalling, with known associations to health and disease. Study of their functional-
ities has intensiﬁed thanks to the development of various analytical strategies, with particular con-
tribution from differential alkylation-based proteomics methods. Presented here is a critical evaluation of
differential alkylation-based strategies for the analysis of S-nitrosylation and S-sulfenylation. The aim is
to assess the current status and to provide insights for future directions in the dynamically evolving ﬁeld
of redox proteomics. To achieve that we collected 35 original research articles published since 2010 and
analysed them considering the following parameters, (i) resolution of modiﬁcation site, (ii) quantitative
information, including correction of modiﬁcation levels by protein abundance changes and determina-
tion of modiﬁcation site occupancy, (iii) throughput, including the amount of starting material required
for analysis. The results of this meta-analysis are the core of this review, complemented by issues related
to biological models and sample preparation in redox proteomics, including conditions for free thiol
blocking and labelling of target cysteine oxoforms.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Cysteine is one of the least abundant amino acids in prokaryotic
and eukaryotic organisms and it is also amongst the most oxida-
tion-prone one [1]. Due to the strong electronegativity of the
sulphur atom present in the side chain thiolate group cysteine can
exist in many different redox forms inside the cell [1]. The majority
of cysteine oxoforms are reversible and can be reduced to thiol
(SH). These include disulphide bonds (S–S), S-glutathionylation (S-
SG), S-nitrosylation (SNO) and S-sulfenylation (SOH). Sulﬁnic
(SO2H) and sulphonic acid (SO3H) are the two oxoforms that are
chemically irreversible. This is with the exception of eukaryotic
2-Cys peroxiredoxins, where SO2H may be reduced by sulﬁr-
edoxin, in an ATP and Mg2þ-dependant reaction [2–4].
Reactivity of the thiolate extends the range of cysteine's mod-
iﬁcations beyond redox chemistries, e.g. acylation by enzymatic
attachment of lipids [5]. The complete spectrum of cysteine post-
translational modiﬁcations (PTMs) was recently reviewed [6]. The
focus of this review is on redox-based reversible oxidations, SNO
and SOH in particular.
S-nitrosylation is the covalent addition of a nitroso group (NO)
into cysteine's thiolate, directly by reactive nitrogen species (RNS),
e.g. nitrosonium cation (NOþ) or peroxynitrite (ONOO) or in-
directly by reactive oxygen species (ROS) via induction of NO
production [7,8]. It may also result from trans-S-nitrosylation,
transfer of a NO group from S-nitrosylated small molecules, e.g.
S-nitrosoglutathione (GSNO) or S-nitrosylated proteins onto an-
other protein-bound thiolate [7]. Although non-enzymatic, SNO is
selective and transient modiﬁcation which makes it an excellent
signal transducer [9]. SNO of catalytic cysteines may be involved in
regulation of enzyme's activity, e.g. inhibition of aldehyde dehy-
drogenase upon S-nitrosylation [10,11]. Additionally, SNO may also
act as an antioxidant buffer by preventing formation of irreversible
oxidations, as described in the heart during oxidative stress caused
by ischaemia–reperfusion [9].
S-sulfenylation is the oxidation of thiolate to sulfenic acid
which in vivo occurs mainly via reaction with hydrogen peroxide
(H2O2) [12]. SOH is a non-enzymatic modiﬁcation which may also
result from conversion of other cysteine oxoforms, including SNO
[7]. SOH is sub-stoichiometric and transient oxoform which, in an
oxidising environment progresses to SO2H and SO3H. Therefore
SOH has long been regarded as a marker of oxidative damage [13].
However, growing evidence suggests that SOH is also an important
regulatory PTM. For instance, SOH of the active site cysteine in
protein tyrosine phosphatases (PTP1B) reversibly inhibits their
catalytic activity [14].
Both SNO and SOH are well recognised for their role in reg-
ulation of protein activity and protein–protein interaction thereby
actively modulating intracellular signalling, as reviewed in Ref.
[15]. Redox sensitive transcription factors exist in prokaryotes and
eukaryotes and oxidative cysteine modiﬁcations are direct effec-
tors of their functions [16,17]. Their role in maintenance of in-
tracellular redox homoeostasis is equally important. Both SNO and
SOH contribute to antioxidant capacity, in a similar manner to
low-molecular weight thiols e.g. glutathione (GSH) [1]. There is
also a growing body of evidence indicating their involvement in
pathologies and disease conditions, as reviewed in Ref. [15,18].
All of the above make SNO and SOH key targets for basic and
applied research. This was recognised over a decade ago and
resulted in a dynamic development of analytical tools and their
application to redox proteomes (redoxomes). The term redoxome
was coined by Chiappetta et al. in 2010 [19]. It is deﬁned as
complete set of cysteine oxoforms within proteins of a given
proteome. Study of the redoxome may be approached in multiple
ways depending on its complexity and the required depth of
analysis. Previously, global analysis was common. For instance,
Ellman's reagent (5,5′-dithiobis-(2-nitrobenzoic acid), DTNB) re-
acts with SH groups resulting in a coloured product which may be
measured spectrophotometrically at 412 nm. Using the extinction
coefﬁcient for TNB2 , or a standard curve of cysteine, it is possible
to calculate the amount of thiol groups present in a sample/protein
[20]. Additionally, there exist modiﬁcation speciﬁc methods, e.g.
UV photolysis to assess global SNO levels [21]. In both cases the
oxidative state of individual proteins and modiﬁcation sites are
unknown. The limited sensitivity of global methods prevents dis-
tinction of subtle changes caused by typical physiological levels of
oxidative stress.
The above limitations are addressed by proteomics-based
methods. Over the years numerous strategies were developed for
both gel-based and gel-free analysis of redox proteomes. With the
later generally more suited to resolve cysteine oxoforms [22]. The
majority of those methods have been described in detail in several
excellent reviews [1,6,23].
In recent years, the development of redox proteomics has been
driven by application of a method/concept commonly referred to as
differential alkylation. It is a tool to analyse reversible modiﬁcations
of cysteine using speciﬁc reductants and alkylating reagents. Differ-
ential alkylation was introduced in 2001 as a biotin switch for ana-
lysis of SNO and has been evolving since [24]. In time, it was adapted
to other cysteine oxoforms e.g. SOH [25], S-SG [26] and all chemically
reducible cysteine modiﬁcations [27]. Regardless of the target oxo-
form and complexity, the principles remain unchanged. The initial
step is blocking of SH groups. After removal of excess blocking/al-
kylating reagent, modiﬁcation-speciﬁc reductants are added fol-
lowed by blocking/alkylation of nascent thiols with a distinct
blocking/alkylating reagent. Nascent thiols refer to the SH groups
generated upon modiﬁcation-speciﬁc reduction. As above, any excess
reducing/alkylating reagent is removed prior to subsequent steps.
Finally, the remainder of reversible cysteine modiﬁcations are re-
duced with a non-selective reductant and alkylated for stability. This
ﬁnal alkylation step is only applicable if the modiﬁcation speciﬁc
blocking/alkylation is irreversible. When reversible labels (e.g. those
utilising a disulphide bond) are used, this step should be omitted as it
prevents unambiguous assignment of modiﬁcation site. The ﬁnal
step is also omitted where non-selective reducing agents e.g. di-
thiothreitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP) are used
directly after free thiol blocking. Fig. 1 summarises the concept and
main steps of differential alkylation-based redox proteomics
experiments.
This basic workﬂow has been modiﬁed over the years to in-
crease depth of analysis. Nowadays, differential alkylation com-
bined with tandem mass spectrometry is able to characterise en-
tire redox proteomes. This includes analysis of various cysteine
oxoforms simultaneously, with site-speciﬁc resolution [28], esti-
mation of relative abundances [29] and modiﬁcation site occu-
pancies [30].
The aim of this review is a critical evaluation of experimental
setups, including both biological models and methods used for
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differential alkylation-based proteomic analysis of reversible cy-
steine oxidations, SNO and SOH in particular. We provide an
overview of how differential alkylation-based methods have
evolved over the years and the impact they have made on the
depth and precision of SNO/SOH analysis. To facilitate that, we
collected original research publications investigating SNO and SOH
published since 2010. Those were analysed considering the
following features: (i) assignment of modiﬁcation type and site, (ii)
quantitation of modiﬁcation abundance, including correction of
modiﬁcation levels by protein abundance changes and modiﬁca-
tion site occupancy (iii) throughput and amount of starting ma-
terial required. The results of this meta-analysis are the core of this
review. We discuss future directions in the dynamically evolving
ﬁeld of redox proteomics.
Fig. 1. Schematic summary of the principles of differential alkylation for analysis of reversible cysteine oxidations. Proteins are typically dissolved in denaturing buffers
supplemented with metal ion chelators such as EDTA. A. Initially, reduced cysteine thiols (SH) are blocked for stability. Depending on the type of reagent (indicated by ),
blocking might be chemically reversible/reducible (MMTS) or irreversible (NEM, IAM). B. Subsequently, target cysteine oxoforms are reduced to SH groups. Ascorbate alone
and in tandem with Cu2þ selectively reduces S-nitrosothiols. Arsenite selectively reduces S-sulfenylations. Strong reducing reagents like DTT and TCEP reduce all reversible
modiﬁcations, which includes the oxoforms depicted here as well as non-redox modiﬁcations, e.g. acylation. C. Finally, nascent thiols are labelled for stability in reversible
manner (via disulphide bond) or irreversible manner (via alkylation). Labelling reagents are often designed to provide quantitative information about the modiﬁcation site.
indicates: EDTA – ethylenediaminetetraacetic acid; MMTS – methyl methanethiosulfonate; NEM – N-ethylmaleimide; IAM – iodoacetamide; DTT – dithiothreitol; TCEP –
tris(2-carboxyethyl)phosphine).
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Table 1
Selected proteomics/mass spectrometry-based studies (2010-to date) investigating various types of reversible cysteine modiﬁcations.
Reference Cysteine
modiﬁca-
tion
Method Metal ion
chelators (in
lysis buffer)
Free thiol
blocking/alky-
lating reagent
Reductant Labelling
type
Inherent
quantitation
Unambiguous
modiﬁcation
site assignment
Correction of
modiﬁcation
levels by pro-
tein abun-
dance changes
Model system Number of mod-
iﬁed proteins/pep-
tides/sites
Amount of start-
ing material/con-
dition [mg]
[29] SNO iodoTMT™ 1 mM EDTA,
0.1 mM
neocuproine
MMTS 5 mM ascorbate Indirect, ir-
reversible
TMT™ Yes No CysNO-treated BV-2
cells; LPS-stimulated
BV-2 cells; LPS þ SAC
stimulated BV-2 cells
134 Sites 101 sites
115 sites
0.4
[52] SNO cysTMT™ 1 mM EDTA,
0.1 mM
neocuproine
NEM 1 mM
ascorbateþ1 mM
CuSO4
Indirect,
reversible
TMT™ ™No No GSNO-treated HPAEC
cells; CysNo-treated
HPAEC cells
220 Sites; 11-25
sites
0.2; N/a
[34] SNO Phenylmercury
resin
1 mM DTPA,
0.1 mM
neocuproine
MMTS – Direct,
reversible
N/a No þ/ GSNO-treated mouse
liver homogenates
150 Peptides 3
[64] SNO cysTMT™ 1 mM EDTA,
0.1 mM
neocuproine
cysTMT 20 mM ascorbate Indirect,
reversible
TMT™ No þ/ Mouse hearts after
ischaemic insult
275 Peptides after
ischaemic insult
1
[35] SNO Thiopropyl
sepharose
1 mM EDTA,
0.1 mM
neocuproine
NEM 5 mM
ascorbateþ5 mM
CuCl
Indirect,
reversible
iTRAQ þ/ No GSNO-treated mouse
skeletal muscle
homogenates
488 Sites 0.5
[82] SNO Thiopropyl
sepharose
1 mM EDTA,
and 0.1 mM
neocuproine
NEM 20 mM ascorbate Indirect,
reversible
Label-free
using in-house
software
þ/ No GSNO-treated, per-
fused mouse heart
homogenates
42000 Sites 1
[45] SNO Organomercury
resin
1 mM DTPA,
0.1 mM
neocuproine
MMTS – Direct,
reversible
N/a No No Non-stimulated mouse
liver homogenates
328 Peptides 3 and 30
[92] SNO ICAT 1 mM EDTA,
0.1 mM
neocuproine
MMTS 10 mM ascorbate Indirect, ir-
reversible
Light and hea-
vy ICAT
Yes No SNO-Trx treated SH-
SY5Y cell lysates
N/a 0.3
[93] SNO PEO-iodoacetyl-
biotin
1 mM EDTA,
0.1 mM
neocuproine
IAM 5 mM ascorbate Indirect, ir-
reversible
N/a Yes No SNAP/L-cysteine-trea-
ted MS-1 cells
586 Sites 1.5
[94] SNO Thioredoxin trap
mutant
1 mM EDTA,
0.1 mM DTPA;
NEM – Direct,
reversible
N/a No No CysNO-treated THP1
cells; LPS/IFN-γ stimu-
lated RAW264.7 cells
400 Proteins;
200 Proteins
3
[95] SNO ICAT 1 mM EDTA,
0.1 mM
neocuproine
MMTS 10 mM ascorbate Indirect, ir-
reversible
Light and hea-
vy ICAT
Yes No SNO-Trx 1-treated SH-
SY5Y cell lysate
50–76 Sites 0.3
[96] SNO HPDP-biotin 1 mM EDTA,
0.1 mM
neocuproine
MMTS 50 mM ascorbate Indirect,
reversible
N/a No No GSNO-treated re-
combinant human
proteins on chip
834 Proteins N/a
[53] SNO HPDP-biotin 100 mM
neocuproine
NEM 1 mM
ascorbateþ10 mM
CuSO4
Indirect,
reversible
N/a þ/ No mouse with spared
nerve injury
161 Peptides 0.01
[46] SNO Organomercury
resin
1 mM DTPA,
0.1 mM
neocuproine
MMTS – Direct,
reversible
N/a No No 6 Different mouse
tissues
1011 Sites N/a
[28] SNO ICAT 5 mM EDTA,
0.5 mM
neocuproine
MMTS 5 mM
ascorbateþ1 mM
CuCl2
Indirect, ir-
reversible
Light and hea-
vy version of
ICAT
Yes No NaCl-treated Arabi-
dopsis cells
123 Peptides 2
[97] SNO HPDP-biotin 1 mM EDTA,
0.1 mM
neocuproine
MMTS 10 mM ascorbate Indirect,
reversible
N/a þ/ No CysNO-treated NPrEC
cells
82 Sites 1
[98] SNO HPDP-biotin 1 mM EDTA,
0.1 mM
NEM 20 mM ascorbate Indirect,
reversible
SILAC þ/ No LPS and IFN- γ-treated
RAW 264.7 cells
156 Proteins 1
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Table 1 (continued )
Reference Cysteine
modiﬁca-
tion
Method Metal ion
chelators (in
lysis buffer)
Free thiol
blocking/alky-
lating reagent
Reductant Labelling
type
Inherent
quantitation
Unambiguous
modiﬁcation
site assignment
Correction of
modiﬁcation
levels by pro-
tein abun-
dance changes
Model system Number of mod-
iﬁed proteins/pep-
tides/sites
Amount of start-
ing material/con-
dition [mg]
neocuproine
[54] SNO cysTMT™ 1 mM EDTA,
0.1 mM
neocuproine
NEM 1 mM
ascorbateþ1 mM
CuSO4
Indirect,
reversible
TMT™ No No NO donor-treated car-
diac mitochondria
N/a 0.2–0.3
[99] SNO ICAT 5 mM EDTA,
0.5 mM
neocuproine
MMTS 5 mM ascorbate Indirect, ir-
reversible
Light and hea-
vy version of
ICAT
Yes No Control Arabidopsis
cells and NaCl treated
53 Sites 5 sites 2
[77] SNO d5-NEM 1 mM EDTA,
0.1 mM
neocuproine
NEM 5 mM
ascorbateþ1 mM
CuCl
Indirect, ir-
reversible
Isotopomers of
NEM
Yes No CysNO-treated SH-
SY5Y cells
8 Peptides N/a
[57] SNO Biotin maleimide – NEM 30 mM sinapinic
acid
Indirect, ir-
reversible
N/a No No CysNO and LPS-treated
RAW 264.7 cells
N/a N/a
[87] SNOþS-
SG
Gold
nanoparticles
– IAM – Direct,
reversible
N/a þ/ No GSNO-treated PDI and
DUSP12 recombinant
proteins
3 SNO and 5 S-SG
peptides
respectively
N/a
[65] SNO–4-
ARa
IodoTMT™ 1 mM EDTA,
0.1 mM
neocuproine
IAM 20 mM
ascorbate–45 mM
TCEP
Indirect, ir-
reversible
TMT™ Yes No GSNO-treated H9c2
cells under hypoxia
266 sites 0.3
[79] SNO; AR Thiopropyl
sepharose
10 mM EDTA,
0.1 mM neo-
cuproine; TCA
NEM 5 mM
ascorbateþ5 mM
CuCl; 10 mM DTT
Indirect,
reversible
iTRAQ No No GSNO-treated mouse
muscle; RAW
264.7cells
488 SNO sites 0.5; 0.1
[82] SNOþAR Thiopropyl
sepharose
1 mM EDTA,
0.1 mM
neocuproine
NEM 20 mM ascorbate;
10 mM DTT
Indirect,
reversible
N/a No No Mouse hearts sub-
jected to various per-
fusion/ischaemia
protocols
47 SNO sites 1
[78] SNOþAR NEM 1 mM EDTA,
0.1 mM
neocuproine
NEM 5 mM
ascorbateþ1 mM
CuCl; 50 mM TCEP
Indirect, ir-
reversible
Light and hea-
vy version of
NEM
Yes No CysNO-treated SH-
SY5Y
Targeted analysis of
speciﬁc proteins, 11
sites
N/a
[27] S-S/AR ICAT 10% TCA IAM 10 mM TCEP Indirect, ir-
reversible
Light and hea-
vy cleavable
ICAT
Yes Yes H2O2 treated Schizo-
saccharomyces pombe
1195 Peptides 2.1
[85] AR GELSILOX 1 mM EDTA NEM 10 mM DTT Indirect, ir-
reversible
O18 þ/ Yes Proof of principle: dia-
mine-treated EA.
Hy296 cells
254 Sites 0.5
[33] AR ICAT 10% TCA IAM 20 mM TCEP Indirect, ir-
reversible
Light and hea-
vy ICAT
Yes Yes H2O2-treated wt yeast/
Trx1 and Trr1 mutant
yeast
500 Peptides 2
[44] AR Thiopropyl
sepharose
2 mM DTPA NEM 10 mM DTT Indirect,
reversible
Label-free No No Perfused rat heart 6559 peptides N/a
[58] SOH Biotin maleimide 1 mM EDTA,
0.1 mM
neocuproine
Maleimide 20 mM arsenite Indirect, ir-
reversible
N/a No No Kidney medula of
spontaneously hy-
pertensive rats
32 Proteins 5
[43] SOH 1,3- Cyclohex-
adione
derivatives
100 μM DTPA NEM, IAA – Direct, irre-
versible
N/a þ/ No Example labelling of
puriﬁed proteins and
cells
N/a N/a
[32] SOH DAz-2 – – – Direct, irre-
versible
Light and hea-
vy DAz-2
Yes No H2O2-treated C64S
C82S Gpx3
1 Site N/a
[69] SOH Dimedone – Iododimedone – Direct, irre-
versible
Light and hea-
vy dimedone/
iododimedone
Yes No H2O2-treated C64S
C82S Gpx3 and GAPDH
1 Site/protein N/a
[100] SOH Yap1-cCRD 20% TCA IAA – Direct,
reversible
N/a No No H2O2-treated Sacchar-
omyces cerevisiae
42 Proteins N/a
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2. Model systems for studying reversible cysteine oxidations
The choice of model system in redox proteomics is very im-
portant, because they can vary dramatically in the way they re-
semble physiological redox homoeostasis. Therefore both the
choice of biological system and oxidative stimulus are considered
in the following section.
Our meta-analysis had shown that since 2010, there were 12
studies on mammalian tissues/organs, 17 studies on cell lines,
3 studies in yeast, and 5 on puriﬁed proteins (Table 1). Importantly,
only 13 of the 35 studies collected measured endogenous levels of
SNO/SOH. Endogenous refers to physiological (basal) or patholo-
gical (stimuli-induced) levels of oxidation that do not involve di-
rect treatment with ROS/RNS donors. Use of ROS/RNS donors in
vitro is common practise in these studies. GSNO and S-ni-
trosocysteine (CysNO) are typically used to induce SNO. Hydrogen
peroxide (H2O2) is commonly used to generate SOH (Table 1). Al-
though these donors exist in vivo their concentrations used for
SNO/SOH induction in vitro are higher than physiological. To give a
speciﬁc example, intracellular levels of H2O2 vary between 1 and
700 nM in aerobic organisms [31]. The studies we have collected
use between 3.5 and 300 times this concentration [27,32,33]. Such
high concentrations seem excessive considering the excellent
membrane permeability of H2O2 [31]. This is especially true, for
studies that aim to measure cysteine oxidation in vivo [33].
The routine use of harsh oxidising conditions may be justiﬁed
when the sensitivity of detection is insufﬁcient and in cases where
ROS/RNS donors are of limited membrane permeability [15].
However, the physiological relevance of such conditions should
also be considered.
Membrane impermeability to common oxidants may be cir-
cumvented by direct oxidation of protein lysates such as was the
case for 7 of the studies (20%) collected in Table 1, e.g. in Ref.
[34,35]. However, these models are a poor representation of in-
tracellular redox homoeostasis for several reasons. Firstly, cell lysis
abolishes organelle redox microenvironments, altering the redox
status of compartment speciﬁc cysteine oxoforms and introducing
artefactual modiﬁcations. Moreover, small molecule antioxidants
such as GSH may be lost during protein precipitation in acid e.g.
TCA which may affect cysteine's susceptibility to oxidation [36].
Denaturing conditions disregard the role of protein structure and
protein–protein interactions in the susceptibility to oxidation.
They also destabilise labile oxoforms e.g. SOH, creating artefacts as
reviewed in Ref. [37]. All the above makes such in vitro studies
inadequate for analysis of even the most severe physiological in-
sult, however they can be successfully used as models in me-
chanistic studies e.g. when new oxidants are evaluated.
3. Sample preparation for redox proteomics
Due to the high reactivity and instability of cysteine oxoforms
as well as their sub-stoichiometric abundances the conditions
used for protein extraction prior to redox proteomics are ex-
tremely important. Therefore, the following sections are dedicated
to general and modiﬁcation-speciﬁc issues related to sample
preparation.
Cells are heterogeneous redox entities with compartment-
speciﬁc redox activities. For example, the mitochondrial electron
transport chain (ETC) produces large quantities of ROS which do
not appear to the same extent in the cytoplasm [38]. Such com-
partmentalisation is crucial for maintaining redox homoeostasis
and allows the cell to deal with redox stressors at the source. For
instance, rotenone (a membrane permeable pesticide) inhibits
electron ﬂow from Complex I of ETC which increases ROS/RNS
production and oxidative stress in mitochondria. However, as long
as the redox capacity of mitochondria is able to withstand this
toxic insult other cellular compartments remain unaffected [39].
3.1. Cell lysis and protein extraction
The initial step of sample preparation disrupts cellular com-
partmentalisation and creates a homogenous mixture of biomo-
lecules. Considering the rotenone example, cell lysis would mix
the more highly oxidising environment of mitochondria with
compartments in steady-state e.g. nucleus and cytoplasm. ROS/
RNS from mitochondria increase levels of reactive species in the
lysate leading to artiﬁcial changes in redox status of other cellular
cysteines. Although it is not possible to remove these artefacts
completely, they may be minimised by appropriate sample
handling.
There are several points of general importance. Oxygen (O2), its
reactive species and transition metal ions together are a potent
source of hydroxyl radicals (HO) generated via the Fenton reac-
tion [40]. Therefore it is highly recommended that buffers and
working solutions are depleted of O2 and/or contain metal ion
chelators e.g. ethylenediaminetetraacetic acid (EDTA), diethylene-
triaminepentaacetic acid (DTPA) in sufﬁcient concentrations [41].
Neocuproine is a Cuþ chelator, used to prevent Cuþ-catalysed
displacement of NO groups from SNO proteins [42]. However,
neocuproine should be avoided when Cuþ/Cu2þ is used in tandem
with ascorbate for selective reduction of SNO (discussed further
below). According to our meta-analysis, the most common metal
ion chelators used are EDTA and neocuproine which were used
concomitantly in 20 studies (57%) (Table 1). DTPA was also used,
either alone [43,44], in combination with neocuproine [34,45,46]
or EDTA [47].
Due to the reactivity and transient nature of cysteine oxoforms,
sample processing time should be minimised. Processing time
refers to the period from sample stimulation until labelling of
target oxoforms. Continuous analysis with no intermediate storage
is preferred for maximal sensitivity. To give speciﬁc example, we
observed that shortening protein precipitation time from over-
night to 1 h improved SNO signal intensity considerably (data not
shown). This is also in line with Burgoyne and Eaton who re-
commend replacement of lengthy and loss-prone precipitations
with size exclusion chromatography for desalting [15]. Finally, the
majority of cysteine oxoforms, SNO in particular, are light sensi-
tive; therefore all steps from cell disruption until labelling of
nascent thiols should be performed under minimal light exposure
[21].
3.2. Blocking of free thiols
The following paragraphs are dedicated to technical aspects of
sample preparation prior to differential alkylation. This includes
timely and effective blocking of SH groups in order to preserve
in vivo redox status and minimise artefactual modiﬁcations. This is
typically achieved by acid precipitation or by chemical blocking/
alkylation [36]. Each method has certain advantages and limita-
tions as extensively discussed by Hansen and Winther [36]. A
combination of the two, might be the most effective, especially in
analysis of S-nitrosoproteome as SNO groups remain reactive even
under acidic conditions [36].
Typically, samples are lysed in a denaturing buffer, e.g. HENS
buffer (HEPES, EDTA, neocuproine, SDS) containing a blocking (S-
methyl methanethiosulfonate, MMTS) or alkylating reagent (N-
ethylmaleimide, NEM; iodoacetamide, IAM) [36]. Our meta-ana-
lysis revealed that NEM is the most frequently used for blocking of
SH groups (14 studies), followed by MMTS (10 studies) and IAM (6
studies). Each of those reagents poses certain advantages and
limitations and there is no consensus as to which of them to use
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[36,48]. For instance, NEM is a cell permeable alkylating reagent
which irreversibly binds to GSH thereby altering cellular redox
equilibrium [36]. Importantly, despite the controversy, no sys-
tematic study was conducted to offer direct comparison of MMTS,
NEM and IAM in terms of effectiveness, pH dependence and se-
lectivity. Perhaps, such systematic study would put an end to the
long standing dispute over SH blocking. Regardless, SH blocking/
alkylation is critical as any failure or incompleteness at this step
artiﬁcially increases target modiﬁcation levels leading to false
positive results. Therefore it should be thoroughly evaluated by
western blot or MS-based analysis prior to continuation of an
experiment, for every type of sample and experimental condition
(discussed below). Finally, it is crucial to remove any excess
blocking/alkylating reagent prior to subsequent steps. This may be
achieved by protein precipitation or size exclusion chromato-
graphy as reviewed in [36].
4. Application of gel-based strategies in redox proteomics
There exist numerous gel-based strategies for cysteine oxida-
tion analysis, the majority of which are based on differential al-
kylation [1]. Some make use of ﬂuorescently conjugated alkylating
reagents [49,50] others antibody-based detection by western blot,
as reviewed in Ref. [15]. However, in redox proteomics similar to
expression proteomics, gel-free strategies offer improvements in
terms of sensitivity, resolution, quantitation and throughput [1].
We direct the interested reader to reviews where the advantages
and limitations of gel-based approaches to redox proteomics are
described in detail [1,51].
Despite serious limitations, we believe that gel-based strategies
still have a niche in redox proteomics. Paradoxically, one of their
advantages may be their global character which makes them ex-
cellent tools for quality control e.g. to evaluate efﬁciency of SH
blocking. Additionally, they may be used for assessment of global
modiﬁcation levels between experimental conditions, e.g. SNO
levels between control and oxidative stimuli [30]. Such evaluation
saves often expensive reagents and mass spectrometry (MS) ana-
lysis time until all experimental steps and biological models are
fully optimised.
5. Modiﬁcation speciﬁc reduction and labelling of nascent
thiols
In a typical differential alkylation protocol, after initial SH
blocking target cysteine oxoforms are labelled (Fig. 1). This may be
effected by direct reaction of a modiﬁed cysteine with a labelling
reagent or indirectly. In the latter, modiﬁed cysteines are ﬁrst
chemically reduced to SH and those are subsequently labelled in a
reversible (by disulphide bond) or irreversible (by alkylation)
manner. The focus of the following sections is on indirect methods
however due to an increasing number of direct methods a com-
parison of the two approaches is also provided in subsequent
section.
There are few general considerations for how indirect methods
should be performed, regardless of target oxoform. This includes
the reaction conditions. Denaturing buffers are necessary for ef-
fective reduction and alkylation of those cysteines buried within
the tertiary structure of a protein. This is preferred despite the fact
that denaturing conditions might destabilise labile cysteine oxo-
forms [15]. Another decision is whether to label at the protein or
peptide level, which is a dilemma in many modiﬁcomics studies
and is of utmost importance in studies of transient and highly
reactive modiﬁcations, such as oxidations. It is the preference of us
and others that labelling is performed at the protein level [30,35].
This reduces the time between cell disruption and labelling of
target cysteines, minimising sample preparation artefacts. Peptide
level labelling, although preferable for improved accessibility to
modiﬁed residues, is not desired due to signiﬁcantly increased
sample processing time caused by proteolytic digestion. Ad-
ditionally, digestion is typically preceded by DTT/TCEP reduction
and alkylation of cysteines, a step that is not compatible with
speciﬁc SNO/SOH analysis.
After blocking of SH groups, labelling of target oxoforms is
achieved by selective reduction and alkylation. Strong reducing
agents like DTT/TCEP reduce all reversibly oxidised cysteines and
other non-redox modiﬁcations, e.g. acylation. Sodium ascorbate
and sodium arsenite are more selective, reducing SNO and SOH,
respectively. However their actual selectivity is controversial.
5.1. Selective reduction of SNO – ascorbate based
Ascorbate remains the most commonly used reductant of
S-nitrosothiols, even though its selectivity is not clearly deﬁned.
For this reason, over the years of ascorbate usage, variations in its
concentration were used, alone or in tandem with Cu2þ see Ta-
ble 1 [52–54]. The former is more common as it was used in 12
recent studies in the concentration range 5–50 mM. Ascorbate in
combination with Cuþ/Cu2þ was applied in 8 studies and its
concentration ranged between 1 and 5 mM. However, no sys-
tematic study evaluated the concentration dependant selectivity of
SNO reduction and there remains no consensus as to which re-
duction conditions provide superior selectivity and sensitivity of
SNO detection. This is bizarre as the chemistries behind the dif-
ferent approaches are known. Ascorbate in higher concentrations
(e.g. 20 mM) reduces SNO directly, on the basis of nucleophilic
attack [55]. Lower concentrations of ascorbate (e.g. 1 mM) act as
reducing agent only in combination with Cu2þ . Here ascorbate
reduces Cu2þ to Cuþ which in turns reduces SNO [55].
Ascorbate/Cu2þ combination was shown to increase sensitivity of
SNO detection [56] but with no concomitant improvement in se-
lectivity, as discussed in Ref. [15]. Due to the differences in
chemistry, it is crucial not mix the two approaches and use high
ascorbate concentrations in tandem with Cu2þ ions. Although
ascorbate is the most common, other reductants, such as sinapinic
acid have also been used for SNO reduction [57].
5.2. Selective reduction of SOH–arsenite based
Arsenite-based reduction of SOH is less frequent and is typi-
cally replaced by direct labelling with dimedone (discussed in a
subsequent section). According to Table 1 there is only one recent
study where arsenite-based reduction was used to identify SOH
sites from kidney medula of spontaneously hypertensive rats [58].
Due to discrepancies in ascorbate/arsenite-based protocols,
reduction efﬁciency must be evaluated in each experiment in-
cluding appropriate controls. For instance, a control for selectivity
of ascorbate reduction (negative control) would be to irreversibly
block free thiols and UV photolysed SNO groups with one alky-
lating reagent, followed by reduction with ascorbate and alkyla-
tion with an alternative alkylating reagent, such as it was sug-
gested by Forrester et al. [59].
5.3. Non-selective reduction of all reversibly modiﬁed cysteines
Strong reducing agents such as DTT and TCEP are typically used
for reduction of all reversible cysteine modiﬁcations. This includes
reversible oxoforms (disulphides, S-glutathionylation, S-nitrosyla-
tion and S-sulfenylation) as well as non-redox modiﬁcations, e.g.
acylation. According to our analysis DTT and TCEP are used equally
frequent in the concentration range 5–50 mM. When, using DTT it
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is important to remove its excess prior to the labelling/alkylation.
Otherwise SH groups of DTT might compete with SH groups of
target proteins thereby hampering completeness of the labelling.
In case of TCEP, which is a non-thiol based reductant, reduction
and labelling/alkylation might be performed simultaneously. This
is providing that iodoacetamide or maleimide analogues are not
used for labelling/alkylation because they do react with TCEP [36].
Following reduction, labelling of nascent thiols is equally im-
portant (Fig. 1C). Whether provided by manufacturers or de-
termined empirically the key is to establish optimal labelling
conditions. This includes reagent concentration, pH, reaction time,
temperature and other details, e.g. simultaneous versus sequential
reduction and alkylation. Selected aspects of this crucial process
are discussed further in subsequent sections (see Sections 6 and
7). Quenching of the labelling reaction is also important. As we
have recently shown it is necessary to neutralise and remove un-
bound excess tag in order to minimise false positive results [30].
We highly recommend, that all features discussed are empirically
validated in pilot experiments [30].
Overall, perhaps the most pragmatic view on modiﬁcation-
speciﬁc reduction is that inconsistency in reduction conditions and
its controversial selectivity would not be an issue if differential
alkylation-based studies were used exclusively as screening ap-
proaches. Subsequently these data could be veriﬁed with ortho-
gonal strategies including use of anti-SNO-antibody [60] or
OxMRM [61]. These however are still rarely implemented.
6. Reversible versus irreversible methods for labelling of nas-
cent thiols
As mentioned previously, modiﬁcation-speciﬁc reduction is
typically followed by labelling of nascent thiols for stability. De-
pending on the chemistry of the labelling reagent this may result
in either a chemically reversible/reducible or irreversible mod-
iﬁcation of the reduced thiol. Our meta-analysis shows that irre-
versible labelling is slightly more common as it has been applied
to 14 recent studies, as opposed to the 12 studies where reversible
labelling was used. Reversible binding is typically effected by thiol-
disulphide exchange between nascent thiol and disulphide within
the labelling reagent. An example of this is thiopropyl sepharose
resin which provides a fast and convenient method combining
both labelling and selective enrichment of target SH groups prior
to MS-based analysis [62]. Coupling to the resin and enrichment
might be performed at protein or peptide level and according to Su
et al. both approaches provide equally high enrichment efﬁ-
ciencies of over 95% [35]. This allowed the authors to identify 197
SNO proteins, corresponding to 488 SNO sites from GSNO-treated
mouse muscle homogenates [35]. The above example illustrates
that strategies utilising reversible label may prove informative,
when carefully optimised. Generally, however, they do possess
several limitations. The lack of unambiguous modiﬁcation site
assignment is critical, especially when multiple cysteines occupy
the same peptide. Additionally, the generated disulphide bond
prohibits use of reducing agents, e.g. DTT/TCEP prior to proteolytic
digestion which might diminish digestion efﬁciency and ulti-
mately result in lower numbers of identiﬁed peptides.
Much more effective are alkylating reagents (e.g. variants of
iodoacetamide) that irreversibly label nascent SH groups. This
provides a unique mass increase for the modiﬁed peptide which is
unambiguously identiﬁed upon mass measurement (MS spec-
trum). Following that, the site of the modiﬁed cysteine is assigned,
based on the peptide fragmentation pattern (MSMS spectrum).
The prerequisite for a tag of this nature being that it remains intact
upon fragmentation during tandem mass spectrometry.
Isotope-Coded Afﬁnity Tag (ICAT) reagents were amongst the
pioneering irreversible labels, adapted to the redox ﬁeld from
quantitative proteomics [63]. In the recently commercialised cy-
steine reactive Tandem Mass Tag (TMT™) isobaric labels we ob-
serve the tendency to move from reversible to irreversible tags
where the disulphide-based cysTMT™ [52,54,64] was quickly re-
placed with iodoacetyl-based iodoTMT™ [29,30,65]. Considering
their advantages and increasing availability, we believe that irre-
versible tags will dominate redox proteomics studies in the future.
7. Indirect versus direct methods of identifying target cysteine
oxoforms
Differential alkylation-based proteomics methods, such as the
many variations of the biotin switch, rely on replacement of
modiﬁed groups with a stable, identiﬁable molecule. These
methods are therefore indirect and they require appropriate con-
trols and orthogonal validation in order that the results can be
fully relied upon. In contrast, direct methods, aim to preserve
oxidative modiﬁcations in their native form which eliminates
many of the issues with differential alkylation raised above.
Enrichment utilising phenylmercury resin is an example of a
direct method for SNO detection [34,45,46]. It is based on the af-
ﬁnity between sulphur and the mercury cation (Hg2þ) where
upon binding of SNO-containing proteins/peptides NO is hydro-
lysed, stabilising the bond between mercury and the nascent thiol
[66]. Despite the direct binding, the actual site assignment is in-
direct whereby performic acid is used to release bound thiols by
their oxidation to SO3H [45,67]. Although reported complete, such
untargeted oxidation, may still result in ambiguities when multi-
ple reversible cysteine modiﬁcations or endogenous sulphonic
acids are present on the same peptide. Additionally, quantitative
analysis is limited [34], which in part might be due to the com-
plicated sample processing scheme. Therefore, the advancement of
this direct strategy is still far behind differential alkylation-based
proteomics workﬂows.
In contrast to this, direct labelling utilising 5,5-dimethyl-1,3-
cyclohexanedione (dimedone)-based probes is the most reliable
chemistry for detection of intracellular SOH levels [32,43,68,69],
see also Table 1. These reagents label SOH irreversibly without
prior reduction. The newest, cell permeable derivatives of dime-
done allow trapping of SOH groups in vivo, which signiﬁcantly
reduces artefact rates [32,70,71]. Introduced in 2011, isotopically
labelled dimedone and iododimedone analogues allow direct
quantitation of SOH sites, including quantitation of relative SOH
occupancy [69]. Despite these clear advantages, the limitation of
dimedone-based probes is low throughput. Since their introduc-
tion in 2009, dimedone analogues Daz-1 and DAz-2 have been
applied to samples of moderate complexity, e.g. model proteins
[72,73]. In fact, none of the recent dimedone-based studies, re-
ported as many SOH proteins as have been reported from differ-
ential alkylation-based studies, see Table 1. In one of them Tyther
et al. identiﬁed 32 SOH-modiﬁed proteins from kidney medulla of
spontaneously hypertensive rats [58] (Table 1).
The key advantage of differential alkylation-based methods for
analysis of cysteine oxidation is that the same afﬁnity tag can be
incorporated into different oxoforms. This allows for simultaneous
analysis of multiple cysteine oxidations [30]. Using this principle
we developed the SNO/SOH TMT strategy and quantiﬁed 475 SOH
and 479 SNO sites (from 311 proteins) in Escherichia coli under low
and mild oxidative stress [30]. In our most recent study we
quantiﬁed 710 SOH and 986 SNO sites from 569 proteins in human
hepatocarcinoma-derived C3A spheroids under acetaminophen
(APAP) treatment [74]. Such simultaneous analysis allows in-
vestigation of possible cross-talk/interplay between oxidative
PTMs which will be discussed in greater detail in the following
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section.
It is likely that the decreased ambiguity of direct methods
combined with the ﬂexibility of indirect, differential alkylation-
based approaches will be used in concert in the future to achieve a
more complete and accurate coverage of redox proteomes.
8. Determination of modiﬁcation site and type
The Human proteome contains over 21,0000 cysteines which
vary in their susceptibility to oxidation. This is also true even
within a single protein where a multitude of factors contribute to
spatio-temporal redox transitions of individual cysteines. These
are neighbouring amino acids, local pH and the higher order
structure of the protein, just to name few [1,22]. Therefore, site
resolution of the redox proteome is necessary.
There are several requirements to resolve modiﬁcation sites.
Firstly, sites should be irreversibly labelled with a unique tag. Such
a tag provides a characteristic mass increase for the target cy-
steine-containing peptide upon MS analysis. The formula and ﬁnal
mass of the tag is critical because too small tags might not be
easily distinguishable upon MS whereas too large tags might
hamper ionisation of modiﬁed peptides or simply fall outside the
typical m/z range of peptide analysis. Additionally, tags should
remain intact upon both ionisation and fragmentation. Otherwise,
it may complicate MSMS spectrum thereby impeding peptide se-
quencing and assignment of modiﬁcation site, as it is known for
the biotin-based tags [75].
The meta-analysis reveals that 13 recent studies provide un-
ambiguous assignment of modiﬁcation site. In a further 8 studies
resolution of modiﬁcation site may be possible if the target pep-
tide contains only one cysteine residue. Altogether these data in-
dicate clear trend toward quantitative analysis of cysteine
modiﬁcations.
Iodoacetyl Tandem Mass Tags (iodoTMT™) are an example of a
cysteine-reactive tag that facilitates resolution of modiﬁcation site.
This is due to its covalent binding to nascent SH groups which
result in addition of 324.2 Da (iodoTMT™zero) or 329.2 Da (io-
doTMT™-6plex) to a peptide containing a reduced cysteine re-
sidue [65]. The chemical formula of the iodoTMT tag can be easily
implemented into standard proteomic database searches, allowing
for automated modiﬁcation site assignment. Once incorporated,
the tag is inert and remains intact during ionisation and MS ana-
lysis. It does, however, dissociate upon fragmentation, providing a
signature reporter ion in low m/z region of MSMS spectrum which
is used for relative quantitation (discussed in more detail below).
Furthermore, the reporter region is recognised by anti-TMT™ an-
tibody which may be used for selective enrichment of iodoTMT™-
containing peptides from complex peptide mixtures.
Amongst its limitations is a non-speciﬁc labelling of primary
amines when suboptimal conditions for iodoalkylation are used
[76]. This, however, is a common issue of tags containing iodoa-
cetyl groups.
9. Qualitative versus quantitative analysis
Quantitation is nowadays a mandatory component of pro-
teomics analysis. It is also becoming a commonplace in studies of
redox proteomes, as 21 recent studies were conducted in quanti-
tative manner (Table 1). Quantitative information is essential to
characterise dynamic and transient redox proteomes. Amongst all
putative sites, a distinction can be made between those which are
“susceptible” or “sensitive” to the state of the redox environment.
Susceptible sites are those whose redox environment make them
highly oxidised under physiological conditions in the cell.
Sensitive sites are those, which occupy a redox environment in
which they are typically not oxidised but can become modiﬁed
under conditions of oxidative stress. We observed this in a study of
the E. coli redox proteome under low and mild oxidative stress.
From 540 SNO/SOH sites identiﬁed in total only for 6 sites SNO/
SOH levels changed signiﬁcantly between the two conditions [30].
Information about the relative abundance of modiﬁed sites is
crucial to distinguish between susceptible and sensitive sites.
In a typical quantitative experiment, abundance of a modiﬁed
peptide is measured under control and stress conditions and these
values are used to estimate relative fold change of the modiﬁca-
tion. Such relative quantitation may be delivered in numerous
ways. It may be inherent to the differential alkylation, where
quantitative information is typically derived from the cysteine
alkylating reagent e.g. isotopomers of NEM and iodoTMT™
[29,65,77,78]. This was the case for 15 studies collected in Table 1.
It may also be separate from the identiﬁcation of the modiﬁcation
site, for example using dimethyl or iTRAQ-based quantitation
[35,79]. This approach was implemented in the 6 recent studies
(Table 1). Each of these quantitative strategies poses advantages
and limitations which were discussed in detail previously [6,37].
D-Switch was among the ﬁrst quantitative approaches [77]. It
utilises isotopically labelled NEM to quantify target cysteines. In
this method, the pool of SH containing proteins is labelled with
isotopically “light” version of NEM whereas SNO proteins after
selective reduction are labelled with an isotopically “heavy” ver-
sion of NEM. Unfortunately, application of non-isobaric isotopic
labels doubles sample complexity for MS analysis, which decreases
the overall identiﬁcation/quantitation rate. In the original study 11
SNO-containing peptides corresponding to 8 proteins were quan-
tiﬁed from CysNO-treated human neuroblastoma cells [77]. Fur-
thermore, the multiplexing capability is limited to only two
channels.
Both analysis throughput and quantitation depth improved
with introduction of cysteine reactive isobaric labels. A pioneering
study, by Murray et al., reports 25 SNO sites from human pul-
monary artery endothelial (HPAEC) cells after an in-culture sti-
mulation with 200 mM CysNO using the now unavailable reversible
cysTMT™ tags [52]. Development continued with the introduction
of irreversible iodoacetyl Tandem Mass Tags (iodoTMT™). Pan
et al. applied those for sequential quantitation of SNO and all re-
versible cysteine modiﬁcations. In this way, 266 redox sensitive
sites were quantiﬁed in GSNO-treated H9c2 cells under hypoxia
[65].
In one of the most recent studies utilising iodoTMT™, not only
hundreds of modiﬁcation sites were quantiﬁed under near phy-
siological levels of oxidative stress, but also, for the ﬁrst time, si-
multaneous analysis of SNO and SOH was undertaken [30].
Advances in label-free quantitation make it an attractive al-
ternative to chemical labelling-based strategies, due to the re-
duced costs, simpliﬁed protocols and a theoretically unlimited
level of multiplexing. Here quantitative information is extracted
from the chromatographic peak area instead of from the relative
abundance of differentially labelled species. The technical details
of label-free quantitation have been described in numerous re-
views e.g. in Ref. [80,81].
Interestingly, label-free quantitation is still rare in redox pro-
teomics. According to meta-analysis, it was used in only 2 out of
20 recent quantitative studies (Table 1). Kohr et al. applied peak
area based quantitation to measure SNO levels in GSNO-treated
mouse heart homogenates [82]. For the quantitative ratio to be
calculated, the same peptide has to be identiﬁed post enrichment
in both samples. This might be challenging, considering the poor
reproducibility of afﬁnity-based enrichment strategies and the
stochastic nature of data-dependant acquisition (DDA). Further-
more, isobaric labelling-based approaches have the advantage that
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samples are pooled prior to analysis which aids in the detection of
low abundance species. These may be below the limit of detection
in a label-free approach. Considering all the above, we believe that
isobaric labelling will remain a key tool in quantitative redox
proteomics.
10. Correction of modiﬁcation levels by protein abundance
changes
For the PTM to be unambiguously quantiﬁed modiﬁcation
abundances should be corrected by respective changes in protein
abundances [1]. However, such correction was implemented with
moderate success into modiﬁcomics workﬂows [83] and it is a rare
practise in redox proteomics.
The approaches with the potential for such analysis were OxI-
CAT (ICAT – Isotope Coded Afﬁnity Tag) and OxMRM (MRM –
Multiple Reaction Monitoring) [61,84]. This is thanks to the unique
design of the two strategies, which quantify both reduced (SH) and
all reversibly oxidised cysteine oxoforms [61,84]. However neither
of the methods actually applied quantitative information with
intent to correct oxidation abundances by changes in protein
abundances. Instead, they focus on the proportion of oxidised and
non-oxidised cysteines.
Over the years of method development the focus was on more
immediate goals, e.g. alternatives to error-prone modiﬁcation
speciﬁc reduction, implementation of quantitative workﬂows as
well as increasing the overall sensitivity and throughput of the
methods. This trend is evident from our meta-analysis as there are
only 5 recent studies that attempted to correct modiﬁcation levels
by changes in protein abundance [27,33,34,64,85]. In most cases, it
required additional experiments to estimate protein abundance
changes [27,33,85].
Iodoacetyl Tandem Mass Tags (iodoTMT™) allow for simulta-
neous analysis of up to 6 samples/experimental conditions. Alter-
natively, they allow analysis of distinct cysteine subsets between
fewer experimental conditions [30,65]. We showed that labelling
all DTT/TCEP reversible cysteine modiﬁcations with iodoTMT™
allows for sufﬁcient estimation of protein abundance changes [30].
This correction should be more accurate, than using a separate
experiment in parallel, as it guarantees identiﬁcation of the fully
reduced form and quantitation is derived from the same scan as
the modiﬁed species. However, it is important to mention that this
approach does not include the contribution of irreversible oxida-
tions (SO2H and SO3H) to the pool of cysteine modiﬁcations.
Therefore, it is more accurate in the models of moderate oxidative
stress.
To further emphasise the importance of correcting modiﬁcation
levels by protein abundance changes we have performed analysis
of the results from our E. coli study [30]. Fig. 2 shows the average
fold change of SNO/SOH peptides differentially modiﬁed between
low and mild oxidative stress, with and without correction for
protein abundance alterations. It is clear that with no correction
only one site would qualify as differentially regulated.
11. New face of quantitation–modiﬁcation site occupancy
In addition to the relative abundance change, quantitative in-
formation may be used to calculate modiﬁcation site occupancy.
Modiﬁcation site occupancy is the fraction of a residue occupied
by the target modiﬁcation. Occupancy analysis requires that the
total abundance of the site accessible for modiﬁcation is known.
Ideally, this should be the sum of all reversible and irreversible
modiﬁcations of the given cysteine under given conditions. This
however is difﬁcult to achieve practically, as tools for analysis of
SO2H and SO3H are lacking [61].
Therefore, those irreversible modiﬁcations are often excluded
from the pool, justiﬁed by the fact that their contribution is neg-
ligible in most conditions. For instance, Kohr et al. expressed SNO
occupancy in vitro as proportion of SNO to the sum of SH and SNO
abundance [64]. This, however, neglects the contribution of other
abundant cysteine oxoforms, e.g. disulphides [64]. Regardless, this
pioneering study initiated a new trend in quantitative data ana-
lysis and has been actively followed since [30,34,86].
The recently developed SNO/SOH TMT approach allows de-
termination of both SNO and SOH occupancy of any given site
which is calculated in proportion to total reversible cysteine
modiﬁcations. Such simultaneous analysis allowed us to observe
that co-occurring SNO and SOH have distinct occupancies [30].
Additionally, we observed that sites with the highest modiﬁcation
occupancy under treatment/stress conditions are seldom differ-
entially modiﬁed [30]. Finally, we also observed in both bacterial
and mammalian redox proteomes that the average SOH occupancy
is typically lower than the average SNO occupancy [30,74]. This,
however, might be solely a technical issue, related to difﬁculties in
SOH detection [12]. In fact, our observations are contrary to the
ﬁndings of Wang et al. who reported S-oxidation to be more
abundant than S-nitrosylation in CysNO-treated neuroblastoma
cells [78]. Thanks to the above studies, the relevance of in-depth
quantitation of modiﬁcation sites is becoming realised. We sup-
port the view of Murray and Van Eyk, that with available tools
occupancy analysis should be performed routinely in all studies of
redox modiﬁcations [86]. This would allow construction of re-
positories of basal modiﬁcation levels which could be used as a
reference when pathological modiﬁcation levels are measured. We
believe that with future expansion of site occupancy analysis we
will soon be able to determine the key regulatory features of redox
PTMs, e.g. what proportions of modiﬁcation are indicative of sig-
nalling, protection or oxidative damage.
12. Analysis of possible cross-talk between cysteine oxoforms
Previously, when each individual modiﬁcation was analysed
independently, often with conceptually distinct methods, cross-
Fig. 2. Correction of modiﬁcation levels by protein abundance changes is necessary
to determine the true direction of regulation. Presented are SNO/SOH modiﬁcation
sites from Escherichia coli proteins. Those 6 sites were found differentially regulated
between low and mild oxidative stress according to 2 sigma signiﬁcance analysis
performed after correction of modiﬁcation levels by protein abundance changes
(dark grey bars) [30]. The light grey bars represent regulation of those sites, ex-
cluding the correction for change in protein abundance. fraA-ﬂavoprotein subunit
of fumarate reductase FrdA, adhE-aldehyde-alcohol dehydrogenase; narH-re-
spiratory nitrate reductase 1 beta chain.
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talk between cysteine oxoforms was not visible [71]. Technological
advances of recent years, cysteine-reactive isobaric labels in par-
ticular, allow for investigation of potential interplay between cy-
steine oxoforms.
It was again the work of Kohr et al. who were the ﬁrst to
analyse both SNO and a pool of all reversible cysteine modiﬁca-
tions in the same experiment [82]. The analysis is parallel – SNO
proteins are enriched by S-nitrosylation-Resin Assisted Capture
(SNO-RAC) whereas DTT/TCEP reducible oxoforms (Ox) are en-
riched by Ox-RAC. MS analysis is performed separately and the
two subsets are combined afterwards [82]. This elegantly designed
approach, might however suffer from the stochastic nature of
data-dependant acquisition which may not always provide a pair
of SNO and oxidatively modiﬁed peptides.
Nevertheless, the study was critical to set the direction for
concurrent analysis of cysteine oxoforms. Indeed, more studies
followed, which attempted to analyse the interplay of SNO and
other reversible oxoforms in either a simultaneous [82], parallel
[78,79] or sequential manner [65]. In all of these examples,
quantitation is effected by isobaric labelling which facilitates re-
lative abundance comparison between target cysteine subsets. In
particular, the approach by Pan et al. was cleverly designed. They
took advantage of iodoTMT™-6plex multiplexing capability which
allowed quantitative proﬁling of both SNO and the remainder of
reversible cysteine modiﬁcations between 3 experimental condi-
tions. Sequential iodoTMT™-6plex labelling not only reduces the
amount of biological material required but also increases
throughput of the analysis [65]. Combined analysis of distinct cy-
steine oxoforms provided insights into the SNO-guided protection
of cardiomyocytes against oxidative stress upon hypoxia [65].
We intended to take such analysis further with our SNO/SOH
TMT strategy which allows simultaneous analysis of 3 distinct
cysteine subsets: all reversible, SNO and SOH modiﬁcations [30].
Apart from the study by Faccenda et al., this is the ﬁrst approach
allowing quantitative analysis of different cysteine oxoforms si-
multaneously [87]. Due to the fact, that both SNO and SOH are
quantiﬁed from the same MSMS spectrum the co-occurrence is
more apparent and more easily veriﬁed [30]. For instance, we
observed in both bacterial and mammalian models, that majority
of SNO and SOH sites co-occur [30,74].
As reviewed by Evangelista et al. cross-talk between SNO and
SOH seems likely [7]. However, there is certainly room for ex-
pansion in this area, now that quantitative methodologies allow
such simultaneous analysis. We believe that combinatorial analy-
sis should be amongst future directions in redox proteomics and
that it will shed light on the as yet, largely unexplored role of
redox processes in physiology and pathology.
13. Remaining challenges
Despite tremendous improvements of recent years, there re-
main several challenges in redox proteomics. Amongst the most
critical is the amount of starting material required for analysis. Our
meta-analysis revealed that the vast majority of studies require
milligrams of starting material (15 out of 26). A further 10 were
based on higher micrograms (100–500 mg) of cell/tissue samples
(Table 1). In fact there was only one study that used 10 mg of
murine protein extracts to analyse SNO levels in spinal cord after
sciatic nerve injury [53]. High amounts of starting material are
necessary due to sub-stoichiometric and transient nature of cy-
steine oxoforms, loss-prone differential alkylation-based strategies
and limited selectivity of enrichment.
Therefore, we should maximise our efforts to reﬁne labelling
and enrichment protocols in a way that will allow analysis of
human tissue samples and body ﬂuids in the future. We believe
that the key to this will be sequential analysis and orthogonal
fractionation/puriﬁcation strategies that will maximise efﬁciency
and throughput of analysis and will bring us closer to clinical scale
research. This is similar to the technological progression in the
analysis of other PTMs such as phosphorylation [88].
Additional challenges include analysis of reversible cysteine
modiﬁcations from target subcellular locations. Effective organelle
enrichment is often a lengthy process which is contrary to what is
required for preservation of oxidative PTMs. This might be over-
come if more membrane permeable probes like DAz-1, DAz-2 are
developed, allowing for stabilisation of target modiﬁcation prior to
organelle speciﬁc enrichment [71,89].
14. Future directions
Having the proper tools in form of e.g. SNO/SOH TMT workﬂow
the interplay between cysteine oxoforms should be investigated in
various biological systems. This may include calculation of the
likelihood of interdependence between distinct cysteine oxoforms,
as it is applied for analysis of histone modiﬁcations [90].
The integration of quantitative workﬂows that would allow the
study of the interplay between redox and non-redox PTMs such as
phosphorylation and acetylation would also be of importance.
There already exists evidence to support a tight regulatory con-
nection between these two seemingly different classes of PTMs.
For instance it was mentioned by Pan et al. that in the heart, cy-
steine oxoforms might be the triggers and modulators of signalling
cascades exerting cardioprotection [65].
Interplay between SNO and other non-redox PTMs, e.g. pal-
mitoylation and ubiquitination was discussed in an excellent re-
view by Evangelista et al. [7]. We fully support the view and be-
lieve that global, systemic analysis of redox and non-redox PTMs
will broaden our understanding of the intracellular signalling
complexity in health and disease [7].
Amongst the future goals in redox proteomics we see absolute
quantitation as discussed in Ref. [91]. The ﬁrst attempts at “absolute”
quantitation were performed using oxICAT and OxMRM approaches
[61,84]. Unfortunately, only the proportion of oxidised to all re-
versible cysteine oxoforms can be determined, without taking into
account contribution of irreversible modiﬁcations. Additionally, dif-
ﬁculties in the production of synthetic standards currently prohibit
determination of the actual amounts of modiﬁed residues.
15. Conclusions
Redox proteomics is a dynamically evolving ﬁeld and differ-
ential alkylation-based strategies are contributing greatly to its
development. These are ubiquitous in the analysis of virtually any
reversible cysteine modiﬁcation, identifying not only modiﬁed
proteins, but also individual modiﬁcation sites. The majority of
differential alkylation-based proteomics strategies are quantita-
tive, providing information about relative abundance change, al-
though, the tendency is now also toward analysis of modiﬁcation
site occupancy which adds a new dimension to quantitative stu-
dies. We believe that the key for further improvements is the
uniﬁcation of biological models and sample preparation schemes.
This combined with in-depth analysis provided by differential al-
kylation-based proteomics might be sufﬁcient for analysis of en-
dogenous redoxomes in the future.
Funding information
KW – Sino-Danish Center for Education and Research. ARW
– University of Southern Denmark.
K. Wojdyla, A. Rogowska-Wrzesinska / Redox Biology 6 (2015) 240–252250
Acknowledgements
We would like to thank Dr. James Williamson for critical
proofreading of this manuscript.
References
[1] J.M. Held, B.W. Gibson, Regulatory control or oxidative damage? Proteomic
approaches to interrogate the role of cysteine oxidation status in biological
processes, Mol. Cell. Proteom. 11 (4) (2012), R111.013037, http://dx.doi.org/
10.1074/mcp.R111.013037.
[2] B. Biteau, J. Labarre, M.B. Toledano, ATP-dependent reduction of cysteine-
sulphinic acid by S. cerevisiae sulphiredoxin, Nature 425 (6961) (2003)
980–984.
[3] T.S. Chang, W. Jeong, H.A. Woo, S.M. Lee, S. Park, S.G. Rhee, Characterization
of mammalian sulﬁredoxin and its reactivation of hyperoxidized peroxir-
edoxin through reduction of cysteine sulﬁnic acid in the active site to cy-
steine, J. Biol. Chem. 279 (49) (2004) 50994–51001.
[4] S.G. Rhee, W. Jeong, T.S. Chang, H.A. Woo, Sulﬁredoxin, the cysteine sulﬁnic
acid reductase speciﬁc to 2-Cys peroxiredoxin: its discovery, mechanism of
action, and biological signiﬁcance, Kidney Int. Suppl. 106 (2007) S3–S8.
[5] C.T. Tom, B.R. Martin, Fat chance! Getting a grip on a slippery modiﬁcation,
ACS Chem. Biol. 8 (1) (2013) 46–57.
[6] S.M. Couvertier, Y. Zhou, E. Weerapana, Chemical-proteomic strategies to
investigate cysteine posttranslational modiﬁcations, Biochim. Biophys. Acta
1844 (12) (2014) 2315–2330.
[7] A.M. Evangelista, M.J. Kohr, E. Murphy, S-nitrosylation: speciﬁcity, occu-
pancy, and interaction with other post-translational modiﬁcations, Antioxid.
Redox Signal. 19 (11) (2013) 1209–1219.
[8] A. Lin, Y. Wang, J. Tang, P. Xue, C. Li, L. Liu, B. Hu, F. Yang, G.J. Loake, C. Chu,
Nitric oxide and protein S-nitrosylation are integral to hydrogen peroxide-
induced leaf cell death in rice, Plant Physiol. 158 (1) (2012) 451–464.
[9] E. Murphy, M. Kohr, S. Menazza, T. Nguyen, A. Evangelista, J. Sun,
C. Steenbergen, Signaling by S-nitrosylation in the heart, J. Mol. Cell. Cardiol.
73 (2014) 18–25.
[10] K.H. Moon, B.J. Kim, B.J. Song, Inhibition of mitochondrial aldehyde dehy-
drogenase by nitric oxide-mediated S-nitrosylation, FEBS Lett. 579 (27)
(2005) 6115–6120.
[11] K.H. Moon, M.A. Abdelmegeed, B.J. Song, Inactivation of cytosolic aldehyde
dehydrogenase via S-nitrosylation in ethanol-exposed rat liver, FEBS Lett.
581 (21) (2007) 3967–3972.
[12] V. Gupta, K.S. Carroll, Sulfenic acid chemistry, detection and cellular lifetime,
Biochim. Biophys. Acta 1840 (2) (2014) 847–875.
[13] I. Dalle-Donne, A. Scaloni, D. Giustarini, E. Cavarra, G. Tell, G. Lungarella,
R. Colombo, R. Rossi, A. Milzani, Proteins as biomarkers of oxidative/ni-
trosative stress in diseases: the contribution of redox proteomics, Mass
Spectrom. Rev. 24 (1) (2005) 55–99.
[14] A. Salmeen, J.N. Andersen, M.P. Myers, T.C. Meng, J.A. Hinks, N.K. Tonks,
D. Barford, Redox regulation of protein tyrosine phosphatase 1B involves a
sulphenyl-amide intermediate, Nature 423 (6941) (2003) 769–773.
[15] J.R. Burgoyne, P. Eaton, A rapid approach for the detection, quantiﬁcation,
and discovery of novel sulfenic acid or S-nitrosothiol modiﬁed proteins using
a biotin-switch method, Methods Enzymol. 473 (2010) 281–303.
[16] D. Seth, A. Hausladen, Y.J. Wang, J.S. Stamler, Endogenous protein S-Ni-
trosylation in E. coli: regulation by OxyR, Science 336 (6080) (2012) 470–473.
[17] P.D. Ray, B.W. Huang, Y. Tsuji, Reactive oxygen species (ROS) homeostasis and
redox regulation in cellular signaling, Cell. Signal. 24 (5) (2012) 981–990.
[18] H.S. Chung, S.B. Wang, V. Venkatraman, C.I. Murray, J.E. Van Eyk, Cysteine
oxidative posttranslational modiﬁcations: emerging regulation in the cardi-
ovascular system, Circ. Res. 112 (2) (2013) 382–392.
[19] G. Chiappetta, S. Ndiaye, A. Igbaria, C. Kumar, J. Vinh, M.B. Toledano, Pro-
teome screens for Cys residues oxidation: the redoxome, Methods Enzymol.
473 (2010) 199–216.
[20] G.L. Ellman, Tissue sulfhydryl groups, Arch. Biochem. Biophys. 82 (1) (1959)
70–77.
[21] J.S. Stamler, O. Jaraki, J. Osborne, D.I. Simon, J. Keaney, J. Vita, D. Singel, C.
R. Valeri, J. Loscalzo, Nitric oxide circulates in mammalian plasma primarily
as an S-nitroso adduct of serum albumin, Proc. Natl. Acad. Sci. U.S.A. 89 (16)
(1992) 7674–7677.
[22] D.P. Jones, Y.M. Go, Mapping the cysteine proteome: analysis of redox-sen-
sing thiols, Curr. Opin. Chem. Biol. 15 (1) (2011) 103–112.
[23] S. Ratnayake, I.H. Dias, E. Lattman, H.R. Grifﬁths, Stabilising cysteinyl thiol
oxidation and nitrosation for proteomic analysis, J. Proteom. 92 (2013)
160–170.
[24] S.R. Jaffrey, S.H. Snyder, The biotin switch method for the detection of
S-nitrosylated proteins, Sci. STKE 2001 (86) (2001) pl1.
[25] A.T. Saurin, H. Neubert, J.P. Brennan, P. Eaton, Widespread sulfenic acid for-
mation in tissues in response to hydrogen peroxide, Proc. Natl. Acad. Sci. U.S.
A. 101 (52) (2004) 17982–17987.
[26] M.D. Shelton, P.B. Chock, J.J. Mieyal, Glutaredoxin: role in reversible protein
s-glutathionylation and regulation of redox signal transduction and protein
translocation, Antioxid. Redox Signal. 7 (3–4) (2005) 348–366.
[27] S. Garcia-Santamarina, S. Boronat, G. Espadas, J. Ayte, H. Molina, E. Hidalgo,
The oxidized thiol proteome in ﬁssion yeast – optimization of an ICAT-based
method to identify H2O2-oxidized proteins, J. Proteom. 74 (11) (2011)
2476–2486.
[28] A. Fares, C. Nespoulous, M. Rossignol, J.B. Peltier, Simultaneous identiﬁcation
and quantiﬁcation of nitrosylation sites by combination of biotin switch and
ICAT labeling, Methods Mol. Biol. 1072 (2014) 609–620.
[29] Z. Qu, F. Meng, R.D. Bomgarden, R.I. Viner, J. Li, J.C. Rogers, J. Cheng, C.
M. Greenlief, J. Cui, D.B. Lubahn, G.Y. Sun, Z. Gu, Proteomic quantiﬁcation and
site-mapping of S-nitrosylated proteins using isobaric iodoTMT reagents, J.
Proteome Res. 13 (7) (2014) 3200–3211.
[30] K. Wojdyla, J. Williamson, P. Roepstorff, A. Rogowska-Wrzesinska, The SNO/
SOH TMT strategy for combinatorial analysis of reversible cysteine oxida-
tions, J. Proteom. 113 (2015) 415–434.
[31] J.R. Stone, S. Yang, Hydrogen peroxide: a signaling messenger, Antioxid.
Redox Signal. 8 (3–4) (2006) 243–270.
[32] T.H. Truong, F.J. Garcia, Y.H. Seo, K.S. Carroll, Isotope-coded chemical reporter
and acid-cleavable afﬁnity reagents for monitoring protein sulfenic acids,
Bioorg. Med. Chem. Lett. 21 (17) (2011) 5015–5020.
[33] S. Garcia-Santamarina, S. Boronat, A. Domenech, J. Ayte, H. Molina,
E. Hidalgo, Monitoring in vivo reversible cysteine oxidation in proteins using
ICAT and mass spectrometry, Nat. Protoc. 9 (5) (2014) 1131–1145.
[34] P.T. Doulias, M. Tenopoulou, K. Raju, L.A. Spruce, S.H. Seeholzer,
H. Ischiropoulos, Site speciﬁc identiﬁcation of endogenous S-nitrosocysteine
proteomes, J. Proteom. 92 (2013) 195–203.
[35] D. Su, A.K. Shukla, B. Chen, J.S. Kim, E. Nakayasu, Y. Qu, U. Aryal, K. Weitz, T.
R. Clauss, M.E. Monroe, D.G. Camp 2nd, D.J. Bigelow, R.D. Smith, R.
N. Kulkarni, W.J. Qian, Quantitative site-speciﬁc reactivity proﬁling of S-ni-
trosylation in mouse skeletal muscle using cysteinyl peptide enrichment
coupled with mass spectrometry, Free Radic. Biol. Med. 57 (2013) 68–78.
[36] R.E. Hansen, J.R. Winther, An introduction to methods for analyzing thiols
and disulﬁdes: Reactions, reagents, and practical considerations, Anal. Bio-
chem. 394 (2) (2009) 147–158.
[37] S.E. Leonard, K.S. Carroll, Chemical ‘omics’ approaches for understanding
protein cysteine oxidation in biology, Curr. Opin. Chem. Biol. 15 (1) (2011)
88–102.
[38] A. Bachi, I. Dalle-Donne, A. Scaloni, Redox proteomics: chemical principles,
methodological approaches and biological/biomedical promises, Chem. Rev.
113 (1) (2013) 596–698.
[39] T.B. Sherer, R. Betarbet, A.K. Stout, S. Lund, M. Baptista, A.V. Panov, M.
R. Cookson, J.T. Greenamyre, An in vitro model of Parkinson's disease: linking
mitochondrial impairment to altered alpha-synuclein metabolism and oxi-
dative damage, J. Neurosci. 22 (16) (2002) 7006–7015.
[40] B. Halliwell, J.M. Gutteridge, Biologically relevant metal ion-dependent hy-
droxyl radical generation. An update, FEBS Lett. 307 (1) (1992) 108–112.
[41] A. Rogowska-Wrzesinska, K. Wojdyla, O. Nedic, C.P. Baron, H.R. Grifﬁths,
Analysis of protein carbonylation – pitfalls and promise in commonly used
methods, Free Radic. Res. 48 (10) (2014) 1145–1162.
[42] H.H. Al-Sa’doni, I.L. Megson, S. Bisland, A.R. Butler, F.W. Flitney, Neocuproine,
a selective Cu(I) chelator, and the relaxation of rat vascular smooth muscle
by S-nitrosothiols, Br. J. Pharmacol. 121 (6) (1997) 1047–1050.
[43] C. Klomsiri, K.J. Nelson, E. Bechtold, L. Soito, L.C. Johnson, W.T. Lowther, S.
E. Ryu, S.B. King, C.M. Furdui, L.B. Poole, Use of dimedone-based chemical
probes for sulfenic acid detection evaluation of conditions affecting probe
incorporation into redox-sensitive proteins, Methods Enzymol. 473 (2010)
77–94.
[44] J. Paulech, N. Solis, A.V. Edwards, M. Puckeridge, M.Y. White, S.J. Cordwell,
Large-scale capture of peptides containing reversibly oxidized cysteines by
thiol-disulﬁde exchange applied to the myocardial redox proteome, Anal.
Chem. 85 (7) (2013) 3774–3780.
[45] P.T. Doulias, J.L. Greene, T.M. Greco, M. Tenopoulou, S.H. Seeholzer, R.
L. Dunbrack, H. Ischiropoulos, Structural proﬁling of endogenous S-ni-
trosocysteine residues reveals unique features that accommodate diverse
mechanisms for protein S-nitrosylation, Proc. Natl. Acad. Sci. U.S.A. 107 (39)
(2010) 16958–16963.
[46] P.T. Doulias, M. Tenopoulou, J.L. Greene, K. Raju, H. Ischiropoulos, Nitric oxide
regulates mitochondrial fatty acid metabolism through reversible protein
S-nitrosylation, Sci. Signal. 6 (256) (2013) rs1.
[47] S. Ben-Lulu, T. Ziv, A. Admon, P. Weisman-Shomer, M. Benhar, A substrate
trapping approach identiﬁes proteins regulated by reversible S-nitrosylation,
Mol. Cell. Proteom. 13 (10) (2014) 2573–2583.
[48] A.R. Karala, L.W. Ruddock, Does s-methyl methanethiosulfonate trap the
thiol-disulﬁde state of proteins? Antioxid. Redox Signal. 9 (4) (2007)
527–531.
[49] T.R. Hurd, T.A. Prime, M.E. Harbour, K.S. Lilley, M.P. Murphy, Detection of
reactive oxygen species-sensitive thiol proteins by redox difference gel
electrophoresis: implications for mitochondrial redox signaling, J. Biol.
Chem. 282 (30) (2007) 22040–22051.
[50] I.M. Riederer, B.M. Riederer, Differential protein labeling with thiol-reactive
infrared DY-680 and DY-780 maleimides and analysis by two-dimensional
gel electrophoresis, Proteomics 7 (11) (2007) 1753–1756.
[51] G. Mermelekas, M. Makridakis, T. Koeck, A. Vlahou, Redox proteomics: from
residue modiﬁcations to putative biomarker identiﬁcation by gel- and LC–
MS-based approaches, Expert Rev. Proteom. 10 (6) (2013) 537–549.
[52] C.I. Murray, H. Uhrigshardt, R.N. O’Meally, R.N. Cole, J.E. Van Eyk, Identiﬁ-
cation and quantiﬁcation of S-nitrosylation by cysteine reactive tandem
K. Wojdyla, A. Rogowska-Wrzesinska / Redox Biology 6 (2015) 240–252 251
mass tag switch assay, Mol. Cell. Proteom. 11 (2) (2012), M111.013441, http://
dx.doi.org/10.1074/mcp.M111.013441.
[53] R. Scheving, I. Wittig, H. Heide, B. Albuquerque, M. Steger, U. Brandt,
I. Tegeder, Protein S-nitrosylation and denitrosylation in the mouse spinal
cord upon injury of the sciatic nerve, J. Proteom. 75 (13) (2012) 3987–4004.
[54] C.I. Murray, H.S. Chung, H. Uhrigshardt, J.E. Van Eyk, Quantiﬁcation of mi-
tochondrial S-nitrosylation by CysTMT(6) switch assay, Methods Mol. Biol.
1005 (2013) 169–179.
[55] A.J. Holmes, D.L.H. Williams, Reaction of ascorbic acid with S-nitrosothiols:
clear evidence for two distinct reaction pathways, J. Chem. Soc.: Perkin Trans.
2 8 (2000) 1639–1644.
[56] X. Wang, N.J. Kettenhofen, S. Shiva, N. Hogg, M.T. Gladwin, Copper depen-
dence of the biotin switch assay: modiﬁed assay for measuring cellular and
blood nitrosated proteins, Free Radic. Biol. Med. 44 (7) (2008) 1362–1372.
[57] V.M. Kallakunta, A. Staruch, B. Mutus, Sinapinic acid can replace ascorbate in
the biotin switch assay, Biochim. Biophys. Acta 1800 (1) (2010) 23–30.
[58] R. Tyther, A. Ahmeda, E. Johns, B. McDonagh, D. Sheehan, Proteomic proﬁling
of perturbed protein sulfenation in renal medulla of the spontaneously hy-
pertensive rat, J. Proteome Res. 9 (5) (2010) 2678–2687.
[59] M.T. Forrester, M.W. Foster, M. Benhar, J.S. Stamler, Detection of protein
S-nitrosylation with the biotin-switch technique, Free Radic. Biol. Med. 46
(2) (2009) 119–126.
[60] A.J. Gow, C.W. Davis, D. Munson, H. Ischiropoulos, Immunohistochemical
detection of S-nitrosylated proteins, Methods Mol. Biol. 279 (2004) 167–172.
[61] J.M. Held, S.R. Danielson, J.B. Behring, C. Atsriku, D.J. Britton, R.L. Puckett,
B. Schilling, J. Campisi, C.C. Benz, B.W. Gibson, Targeted quantitation of site-
speciﬁc cysteine oxidation in endogenous proteins using a differential al-
kylation and multiple reaction monitoring mass spectrometry approach,
Mol. Cell. Proteom. 9 (7) (2010) 1400–1410.
[62] M.T. Forrester, J.W. Thompson, M.W. Foster, L. Nogueira, M.A. Moseley, J.
S. Stamler, Proteomic analysis of S-nitrosylation and denitrosylation by re-
sin-assisted capture, Nat. Biotechnol. 27 (6) (2009) 557–559.
[63] S.P. Gygi, B. Rist, S.A. Gerber, F. Turecek, M.H. Gelb, R. Aebersold, Quantitative
analysis of complex protein mixtures using isotope-coded afﬁnity tags, Nat.
Biotechnol. 17 (10) (1999) 994–999.
[64] M.J. Kohr, A. Aponte, J. Sun, M. Gucek, C. Steenbergen, E. Murphy, Mea-
surement of S-nitrosylation occupancy in the myocardium with cysteine-
reactive tandem mass tags: short communication, Circ. Res. 111 (10) (2012)
1308–1312.
[65] K.T. Pan, Y.Y. Chen, T.H. Pu, Y.S. Chao, C.Y. Yang, R.D. Bomgarden, J.C. Rogers, T.
C. Meng, K.H. Khoo, Mass spectrometry-based quantitative proteomics for
dissecting multiplexed redox cysteine modiﬁcations in nitric oxide-protected
cardiomyocyte under hypoxia, Antioxid. Redox Signal. 20 (9) (2014)
1365–1381.
[66] B. Saville, A scheme for the colorimetric determination of microgram
amounts of thiols, Analyst 83 (993) (1958) 670–672.
[67] J.J. Pesavento, B.A. Garcia, J.A. Streeky, N.L. Kelleher, C.A. Mizzen, Mild per-
formic acid oxidation enhances chromatographic and top down mass spec-
trometric analyses of histones, Mol. Cell. Proteom. 6 (9) (2007) 1510–1526.
[68] L.V. Benitez, W.S. Allison, The inactivation of the acyl phosphatase activity
catalyzed by the sulfenic acid form of glyceraldehyde 3-phosphate dehy-
drogenase by dimedone and oleﬁns, J. Biol. Chem. 249 (19) (1974)
6234–6243.
[69] Y.H. Seo, K.S. Carroll, Quantiﬁcation of protein sulfenic acid modiﬁcations
using isotope-coded dimedone and iododimedone, Angew. Chem. Int. Ed.
Engl. 50 (6) (2011) 1342–1345.
[70] Y.H. Seo, K.S. Carroll, Facile synthesis and biological evaluation of a cell-
permeable probe to detect redox-regulated proteins, Bioorg. Med. Chem.
Lett. 19 (2) (2009) 356–359.
[71] S.E. Leonard, K.G. Reddie, K.S. Carroll, Mining the thiol proteome for sulfenic
acid modiﬁcations reveals new targets for oxidation in cells, ACS Chem. Biol.
4 (9) (2009) 783–799.
[72] Z. Cheng, J. Wu, A. Setterdahl, K. Reddie, K. Carroll, L.A. Hammad, J.A. Karty, C.
E. Bauer, Activity of the tetrapyrrole regulator CrtJ is controlled by oxidation
of a redox active cysteine located in the DNA binding domain, Mol. Microbiol.
85 (4) (2012) 734–746.
[73] T.J. Barrett, D.I. Pattison, S.E. Leonard, K.S. Carroll, M.J. Davies, C.L. Hawkins,
Inactivation of thiol-dependent enzymes by hypothiocyanous acid: role of
sulfenyl thiocyanate and sulfenic acid intermediates, Free Radic. Biol. Med.
52 (6) (2012) 1075–1085.
[74] K. Wojdyla, Development of Proteomics Methods for Investigation of Oxi-
dised Proteins, in Biochemistry and Molecular Biology, University of South-
ern Denmark, Odense, 2014.
[75] Y. Oda, T. Nagasu, B.T. Chait, Enrichment analysis of phosphorylated proteins
as a tool for probing the phosphoproteome, Nat. Biotechnol. 19 (4) (2001)
379–382.
[76] E.S. Boja, H.M. Fales, Overalkylation of a protein digest with iodoacetamide,
Anal. Chem. 73 (15) (2001) 3576–3582.
[77] V. Sinha, G.T. Wijewickrama, R.E. Chandrasena, H. Xu, P.D. Edirisinghe, I.
T. Schiefer, G.R. Thatcher, Proteomic and mass spectroscopic quantitation of
protein S-nitrosation differentiates NO-donors, ACS Chem. Biol. 5 (2010)
667–680.
[78] Y.T. Wang, S.C. Piyankarage, D.L. Williams, G.R. Thatcher, Proteomic proﬁling
of nitrosative stress: protein S-oxidation accompanies S-nitrosylation, ACS
Chem. Biol. 9 (3) (2014) 821–830.
[79] J. Guo, M.J. Gaffrey, D. Su, T. Liu, D.G. Camp 2nd, R.D. Smith, W.J. Qian, Resin-
assisted enrichment of thiols as a general strategy for proteomic proﬁling of
cysteine-based reversible modiﬁcations, Nat. Protoc. 9 (1) (2014) 64–75.
[80] K.A. Neilson, N.A. Ali, S. Muralidharan, M. Mirzaei, M. Mariani,
G. Assadourian, A. Lee, S.C. van Sluyter, P.A. Haynes, Less label, more free:
approaches in label-free quantitative mass spectrometry, Proteomics 11 (4)
(2011) 535–553.
[81] M. Bantscheff, M. Schirle, G. Sweetman, J. Rick, B. Kuster, Quantitative mass
spectrometry in proteomics: a critical review, Anal. Bioanal. Chem. 389 (4)
(2007) 1017–1031.
[82] M.J. Kohr, A.M. Aponte, J. Sun, G. Wang, E. Murphy, M. Gucek, C. Steenbergen,
Characterization of potential S-nitrosylation sites in the myocardium, Am. J.
Physiol. Heart Circ. Physiol. 300 (4) (2011) H1327–H1335.
[83] J.V. Olsen, M. Mann, Status of large-scale analysis of post-translational
modiﬁcations by mass spectrometry, Mol. Cell. Proteom. 12 (12) (2013)
3444–3452.
[84] L.I. Leichert, F. Gehrke, H.V. Gudiseva, T. Blackwell, M. Ilbert, A.K. Walker, J.
R. Strahler, P.C. Andrews, U. Jakob, Quantifying changes in the thiol redox
proteome upon oxidative stress in vivo, Proc. Natl. Acad. Sci. U.S.A. 105 (24)
(2008) 8197–8202.
[85] P. Martinez-Acedo, E. Nunez, F.J. Gomez, M. Moreno, E. Ramos, A. Izquierdo-
Alvarez, E. Miro-Casas, R. Mesa, P. Rodriguez, A. Martinez-Ruiz, D.G. Dorado,
S. Lamas, J. Vazquez, A novel strategy for global analysis of the dynamic thiol
redox proteome, Mol. Cell. Proteom. 11 (9) (2012) 800–813.
[86] C.I. Murray, J.E. Van Eyk, A twist on quantiﬁcation: measuring the site oc-
cupancy of S-nitrosylation, Circ. Res. 111 (10) (2012) 1253–1255.
[87] A. Faccenda, C.A. Bonham, P.O. Vacratsis, X. Zhang, B. Mutus, Gold nano-
particle enrichment method for identifying S-nitrosylation and S-glutathio-
nylation sites in proteins, J. Am. Chem. Soc. 132 (33) (2010) 11392–11394.
[88] K. Engholm-Keller, P. Birck, J. Storling, F. Pociot, T. Mandrup-Poulsen, M.
R. Larsen, TiSH – a robust and sensitive global phosphoproteomics strategy
employing a combination of TiO2, SIMAC, and HILIC, J. Proteom. 75 (18)
(2012) 5749–5761.
[89] K.G. Reddie, Y.H. Seo, W.B. Muse Iii, S.E. Leonard, K.S. Carroll, A chemical
approach for detecting sulfenic acid-modiﬁed proteins in living cells, Mol.
Biosyst. 4 (6) (2008) 521–531.
[90] V. Schwammle, C.M. Aspalter, S. Sidoli, O.N. Jensen, Large scale analysis of co-
existing post-translational modiﬁcations in histone tails reveals global ﬁne
structure of cross-talk, Mol. Cell. Proteom. 13 (7) (2014) 1855–1865.
[91] M. Thamsen, U. Jakob, The redoxome: proteomic analysis of cellular redox
networks, Curr. Opin. Chem. Biol. 15 (1) (2011) 113–119.
[92] C. Wu, A.M. Parrott, T. Liu, A. Beuve, H. Li, Functional proteomics approaches
for the identiﬁcation of transnitrosylase and denitrosylase targets, Methods
62 (2) (2013) 151–160.
[93] Y.J. Chen, W.C. Ku, P.Y. Lin, H.C. Chou, K.H. Khoo, Y.J. Chen, S-alkylating la-
beling strategy for site-speciﬁc identiﬁcation of the s-nitrosoproteome, J.
Proteome Res. 9 (12) (2010) 6417–6439.
[94] S. Ben-Lulu, T. Ziv, A. Admon, P. Weisman-Shomer, M. Benhar, A substrate
trapping approach identiﬁes proteins regulated by reversible S-nitrosylation,
Mol. Cell. Proteom. 13 (2014) 2573–2583.
[95] C. Wu, A.M. Parrott, T. Liu, M.R. Jain, Y. Yang, J. Sadoshima, H. Li, Distinction of
thioredoxin transnitrosylation and denitrosylation target proteins by the
ICAT quantitative approach, J. Proteom. 74 (11) (2011) 2498–2509.
[96] Y.I. Lee, D. Giovinazzo, H.C. Kang, Y. Lee, J.S. Jeong, P.T. Doulias, Z. Xie, J. Hu,
M. Ghasemi, H. Ischiropoulos, J. Qian, H. Zhu, S. Blackshaw, V.L. Dawson, T.
M. Dawson, Protein microarray characterization of the S-nitrosoproteome,
Mol. Cell. Proteom. 13 (1) (2014) 63–72.
[97] Y.W. Lam, Y. Yuan, J. Isaac, C.V. Babu, J. Meller, S.M. Ho, Comprehensive
identiﬁcation and modiﬁed-site mapping of S-nitrosylated targets in pros-
tate epithelial cells, PLoS One 5 (2) (2010) e9075.
[98] F. Torta, A. Bachi, Quantitative analysis of S-nitrosylated proteins, Methods
Mol. Biol. 893 (2012) 405–416.
[99] A. Fares, M. Rossignol, J.B. Peltier, Proteomics investigation of endogenous
S-nitrosylation in Arabidopsis, Biochem. Biophys. Res. Commun. 416 (3–4)
(2011) 331–336.
[100] C.L. Takanishi, M.J. Wood, A genetically encoded probe for the identiﬁcation
of proteins that form sulfenic acid in response to H2O2 in Saccharomyces
cerevisiae, J. Proteome Res. 10 (6) (2011) 2715–2724.
K. Wojdyla, A. Rogowska-Wrzesinska / Redox Biology 6 (2015) 240–252252
